Cana­di­an biotech to dis­con­tin­ue omega-3 pro­gram af­ter sec­ond PhI­II fails on sig­nif­i­cant triglyc­eride re­duc­tion

It’s been an event­ful 12 months or so for the omega-3 mar­ket, but one com­pa­ny’s lat­est at­tempt to use the ap­proach for se­vere hy­per­triglyc­eridemia came …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.